Low data variability

Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.

We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.

Learn more about our ECG Lab

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.

Learn more about our Cardio Analysis Services

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.

Learn more about our expert cardiologists

Our specialist services

Adaptive Phase I & II
Adaptive Phase III
TQT Studies
Bridging Studies
Patient Recruitment
Data Management
YOU ARE HERE: HOME > NEWS

Association for Human Pharmacology in the Pharmaceutical Industry conference 2022: Impending change, innovations and future challenges.

15
November 2023

The AHPPI conference unfolded as a dynamic exploration of the ever-evolving landscape of early phase clinical drug development.

View Articles

Richmond Pharmacology Boosts Snowsfields School Library with STEM Book Donation on World STEM Day 2023

10
November 2023

Snowsfields School Library has received 50 books about science, technology, engineering and maths (STEM) thanks to a donation from Richmond Pharmacology

View Articles

A Prospective, Observational Study of Bleeding and Quality of Life in Patients with Glanzmann Thrombasthenia in the United Kingdom: Updated Results

2
November 2023

New insights from a prospective study on Glanzmann thrombasthenia (GT) have been published in Blood (2023).

View Articles

A Phase 1/2, First-in-Human, Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participants with Glanzmann Thrombasthenia

2
November 2023

Exciting findings from a Phase 1/2 first-in-human study on HMB-001 for Glanzmann thrombasthenia have been published in Blood (2023).

View Articles

Employee Well-Being: A Commitment that Defines Richmond

2
October 2023

Dr. Junko Ono, the Occupational Support Manager at Richmond Pharmacology provides her insights on fostering a positive work environment.

View Articles

Promising Results for Zilebesiran in Phase 1 Study

29
September 2023

We are pleased to share the findings from our recent Phase 1 study, which investigated the potential of Zilebesiran, an investigational RNA interference therapeutic.

View Articles

Meet the experts

Richmond Pharmacology has a team of experts with extensive knowledge of clinical research trials.

Careers at Richmond

We are on the lookout for people who love what they do, strive for excellence and who want to make a difference.

Our Videos

Learn more about Richmond Pharmacology by viewing some of our videos.

Latest news

Patient safety is not an afterthought. Explore our new infographic!

September 17, 2025
Patient safety is not an afterthought; it is the foundation of every clinical trial.
Read more

Events

JSCPT 2025

5 – 6 December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event
© 2025 Richmond Pharmacology - all rights reserved
Disclaimer
|
Sitemap
|
Privacy Policy
|
Report A Concern
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
PreferencesRejectAccept